Status:
COMPLETED
Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes
Lead Sponsor:
Novartis
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This is a 28-week extension to a study of the safety and effectiveness of three doses of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with t...
Eligibility Criteria
Inclusion
- Only patients successfully completing study CLAF237A2301 are eligible
- Written informed consent
- Ability to comply with all study requirements
Exclusion
- Premature discontinuation from study CLAF237A2301
- Other protocol-defined exclusion criteria may apply
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2006
Estimated Enrollment :
440 Patients enrolled
Trial Details
Trial ID
NCT00138541
Start Date
October 1 2004
End Date
April 1 2006
Last Update
March 1 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936